Economic burden of hypoglycemia in patients with Type 2 diabetes

School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, New Orleans, LA 70112, USA.
Expert Review of Pharmacoeconomics & Outcomes Research (Impact Factor: 1.67). 02/2012; 12(1):47-51. DOI: 10.1586/erp.11.87
Source: PubMed

ABSTRACT Hypoglycemia is an acute complication of diabetes that increases morbidity, mortality and economic costs of diabetes. It presents major clinical problems for the management of Type 2 diabetes as this disease represents the great majority of all diabetes cases. Hypoglycemia makes it difficult for some individuals to achieve good glycemic control, reduces quality of life and increases the burden of diabetes to healthcare systems. Understanding hypoglycemia risk factors can help patients with Type 2 diabetes to correct and avoid hypoglycemia. Recently, an increased risk of hypoglycemia with intensive glycemic control has been identified as an important problem in optimally controlling blood glucose levels in patients with Type 2 diabetes.

46 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adding glucagon-like peptide-1 (GLP-1) receptor agonists to insulin therapy for patients with type 2 diabetes mellitus (T2DM): why and how patients with T2DM who progress to insulin therapy usually do so by starting with a single injection of a long-acting insulin analog, added to oral anti-diabetic drugs. Long-acting insulin analogs provide basal insulin coverage and address elevated fasting blood glucose levels. Because of the near universal efficacy of insulin, such approaches are almost always successful in lowering blood glucose levels, but may not bring patients to goal because they do not address postprandial hyperglycemia. The approach to postprandial hyperglycemia has typically been to add doses of rapid-acting insulin analogs before meals. However, this may increase the risk of hypoglycemia and weight gain, and may not be acceptable to patients both in terms of patient tolerability and adherence. New approaches include the addition of GLP-1 receptor agonists to insulin in patients with uncontrolled T2DM. This article reviews the data and the clinical context of such action with respect to issues of glycemic efficacy, patient tolerability, and safety.
    Osteopathic Family Physician 01/2013; 5(1):51–57. DOI:10.1016/j.osfp.2012.11.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To review and discuss the risks and impact of hypoglycemia and provide guidance for the prevention of hypoglycemia in type 2 diabetes (T2DM).Methods: We review and discuss the risks and impact of hypoglycemia, providing specific guidance regarding the prevention of hypoglycemia and judicial selection of glucose-lowering agents in individuals with T2DM.Results: Hypoglycemia in type 2 diabetes (T2DM) is under-recognized and under-reported. Emerging evidence from large clinical trials suggest that hypoglycemia may be an important risk factor for morbidity and mortality in T2DM. In addition, hypoglycemia is associated with poorer quality of life, greater healthcare utilization costs, and poor adherence to medical regiments.Conclusion: These findings have led professional organizations to emphasize the prevention of hypoglycemia as an important consideration when initiating or intensifying treatment regimens. In clinical settings, particular attention should be paid to a patient's risk for hypoglycemia when initiating or intensifying the pharmacological treatment regimen. Furthermore, the endocrinologist can play an important role in educating not only the patient, but also other members of the diabetes-management team regarding the need for individualized therapy.
    Endocrine Practice 02/2013; 19(3):1-33. DOI:10.4158/EP13005.RA · 2.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are different second line glucose lowering drugs whose efficacy, safety and economic profile have not been established in our setting. We have analyzed the clinical (diabetic treatment adherence, metabolic control, hypoglycemia and macrovascular complications) and economic (resource use and costs) consequences of the combination of metformin with dipeptidyl peptidase inhibitors (DPPIV) in patients with type 2 diabetes. We conducted a multicenter, observational and retrospective study. Patients ≥30 years treated with metformin who initiated a second antidiabetic treatment during 2008-2009 were enrolled in the study. Two groups of patients were established: a) metformin with DPPIV and metformin with other diabetic drugs. The main measurements were comorbidity, compliance/persistence, metabolic control (glycosylated hemoglobin <7%), complications (hypoglycemia, macrovascular) and total costs. Patients were followed-up for 2 years. A total of 2,067 patients were enrolled (mean age: 66.6 years, 53.1% male). Of these, 519 patients (25.1%) were analyzed in the metformin+DPPIV group and 1,548 patients (74.9%) in the group metformin+other antidiabetic drug. The DPPIV group patients showed better compliance (70.3 vs. 59.6%), persistence (63.4 vs. 51.0%) and metabolic control (64.3 vs. 59.6%), respectively (P<.001) compared to the other group. They also showed a lower proportion of hypoglycemia (13.9 vs. 44.3%), cardiovascular events (3.7 vs. 7.6%) and total costs (2,347 vs. € 2,682), P<.05. Despite the limitations of the study, patients treated with metformin associated to DPPIV were more likely to show increased adherence, metabolic control and lower rates of hypoglycemia than those treated with metformin associated to other antidiabetics.
    Revista Clínica Española 07/2013; 213(8). DOI:10.1016/j.rce.2013.06.003 · 1.06 Impact Factor
Show more